MAZE
Maze Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 212.46K | New | $2.34M | 0.0% | New | 1 | SEC ↗ ×2 |
| 2 | State Street Global Advisors ✦ (passive) | 64.71K | New | $712,490 | 0.0% | New | 1 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 20.00K | New | $220,200 | 0.0% | New | 1 | SEC ↗ |
| 4 | Marshall Wace ✦ | 19.60K | New | $215,763 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Geode Capital Management | $2.34M | 0.0% |
| State Street Global Advisors | $712,490 | 0.0% |
| Citadel Advisors | $220,200 | 0.0% |
| Marshall Wace | $215,763 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 164 holders, 51.62M shares, $1.52B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 31.91K sh · $862,186
Officer, Director · 2.59K sh · $70,073
Officer · 16.14K sh · $434,743
Officer · 7.50K sh · $202,921
Officer · 9.71K sh · $254,502
Officer · 59 sh · $1,521
Officer · 5.13K sh · $133,448
Officer, Director · 129 sh · $3,325
Officer, Director · 11.28K sh · $293,482
Officer · 36 sh · $929
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology